marmara med j Marmara Medical Journal 1019-1941 1309-9469 Marmara University 10.5472/marumj.1244684 Clinical Sciences Klinik Tıp Bilimleri The effect of preemptive use of plerixafor on stem cell mobilization in patients with lymphoma and multiple myeloma https://orcid.org/0000-0002-5581-8104 Uysal Ayse FIRAT UNIVERSITY https://orcid.org/0000-0002-3285-417X Erkurt Mehmet Ali INONU UNIVERSITY https://orcid.org/0000-0001-6126-0816 Kuru Irfan INONU UNIVERSITY https://orcid.org/0000-0001-8605-8497 Kaya Emin INONU UNIVERSITY https://orcid.org/0000-0003-3312-8476 Berber Ilhami INONU UNIVERSITY https://orcid.org/0000-0002-5916-0119 Sarıcı Ahmet Malatya Training and Research Hospital https://orcid.org/0000-0001-7498-344X Bıcım Soykan INONU UNIVERSITY https://orcid.org/0000-0002-0742-4629 Kaya Ahmet INONU UNIVERSITY https://orcid.org/0000-0003-3121-7387 Hıdayet Emine INONU UNIVERSITY 01 31 2023 36 1 65 71 08 06 2022 10 27 2022 Copyright © 1988, Marmara Medical Journal 1988 Marmara Medical Journal

ABSTRACTObjective: The aim of this study is to investigate the effect of the preemptive use of plerixafor in patients with lymphoma and multiplemyeloma which was administered as a preemptive single dose to the patients who were determined to have a CD34+ cell count of

 Apheresis Stem cell Mobilization Plerixafor Preemptive Apheresis Stem cell Mobilization Plerixafor Preemptive Ljungman P, Bregni M, Brune M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219-34. doi: 10.1038/ bmt.2009.141 Passweg JR, Baldomero H, Gratwohl A, et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012;47:906-23. doi: 10.1038/bmt.2012.66 Arora S, Majhail NS, Liu H. Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary era. Clin Lymphoma Myeloma Leuk 2019;19:200-5. doi: 10.1016/j.clml.2018.12.010 Mohty M, Hübel K, Kröger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2014;49:865-72. doi: 10.1038/bmt.2014.39 Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol of Blood Marrow Transplant 2014;20:295-308. doi: 10.1016/j. bbmt.2013.10.013 Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocytecolony- stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia Lymphoma 2014;55:331-6. doi: 10.3109/10428.194.2013.802783 Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfusion Apher Sci 2017;56:190- 8. doi: 10.1016/j.transci.2016.11.005 Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-9. doi: 10.1016/j. bbmt.2009.11.012 Lee JL, Kim SB, Lee GW, et al. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields. Transfus Apher Sci 2003;29:29-37. doi: 10.1016/s1473- 0502(03)00097-1 Paripati H, Stewart AK, Cabou S, et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008;22:1282-4. doi: 10.1038/ sj.leu.2405100 Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant 2012;47:342-51. doi: 10.1038/bmt.2011.82 Shah EE, Young RP, Wong SW, et al. Impact of plerixafor use at different peripheral blood cd34(+) thresholds on autologous stem cell collection in patients with multiple myeloma. Blood Marrow Transplant 2020;26:876-83. doi: 10.1016/j. bbmt.2019.11.024 Douglas KW, Gilleece M, Hayden P, et al. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher 2018;33:46-59. doi: 10.1002/jca.21563 Keating GM. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma. Drugs 2011;71:1623-47. doi: 10.2165/11206.040.000000000- 00000 Cooper DL, Medoff E, Patel N, et al. Autologous stem cell mobilization in the age of plerixafor. Clin Lymphoma Myeloma Leuk 2016;16:411-6. doi: 10.1016/j.clml.2016.04.007 Spoerl S, Peter R, Wäscher D, et al. Patients’ outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis. Transfusion 2017;57:115-21. doi: 10.1111/trf.13883 Gambell P, Herbert K, Dickinson M, et al. Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield:an analysis of more than 1,000 collections. Blood Marrow Transplant 2012;18:763-72. doi: 10.1016/j.bbmt.2011.10.002 Szwajcer D, Jennings-Coutts A, Giftakis A, Wall DA. Identification of the CD34 enumeration on the day before stem cell harvest that best predicts poor mobilization. Transfusion 2011;51:587-90. doi: 10.1111/j.1537-2995.2010.02891.x Sancho JM, Morgades M, Grifols JR, et al. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization. Cytotherapy 2012;14:823-9. doi: 10.3109/14653.249.2012.681042 Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-9. doi: 10.1038/bmt.2010.78 Solá C, Maroto P, Salazar R, et al. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophosphamide and filgrastim (r-metHuG-CSF): The CD34+ cell dose positively affects the time to hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology (Amsterdam, Netherlands) 1999;4:195-209. doi: 10.1080/10245.332.1999.11746443 Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher 2017;32:224-34. doi: 10.1002/jca.21496 Micallef IN, Sinha S, Gastineau DA, et al. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Blood Marrow Transplant 2013;19:87-93. doi: 10.1016/j. bbmt.2012.08.010 Vishnu P, Roy V, Paulsen A, Zubair AC. Efficacy and costbenefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012;52:55-62. doi: 10.1111/j.1537-2995.2011.03206.x